J
Johanna Mäenpää
Researcher at University of Tampere
Publications - 109
Citations - 3184
Johanna Mäenpää is an academic researcher from University of Tampere. The author has contributed to research in topics: Ovarian cancer & Endometrial cancer. The author has an hindex of 24, co-authored 105 publications receiving 2174 citations. Previous affiliations of Johanna Mäenpää include Institut Gustave Roussy.
Papers
More filters
Journal ArticleDOI
Revised FIGO staging for carcinoma of the cervix uteri
Neerja Bhatla,Jonathan S. Berek,Mauricio Cuello Fredes,Lynette Denny,Seija Grénman,Kanishka Karunaratne,Sean Kehoe,Ikuo Konishi,Alexander B. Olawaiye,Jaime Prat,Rengaswamy Sankaranarayanan,Rengaswamy Sankaranarayanan,James Brierley,David G. Mutch,Denis Querleu,David Cibula,Michael A. Quinn,Hennie Botha,Lax Sigurd,Laurel W. Rice,Hee-Sug Ryu,Hextan Y.S. Ngan,Johanna Mäenpää,Andri Andrijono,Gatot Purwoto,Amita Maheshwari,Uttam D. Bafna,Marie Plante,Jayashree Natarajan +28 more
TL;DR: To revise FIGO staging of carcinoma of the cervix uteri, allowing incorporation of imaging and/or pathological findings, and clinical assessment of tumor size and disease extent.
Journal ArticleDOI
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
Michelle K. Wilson,Eric Pujade-Lauraine,Daisuke Aoki,Mansoor Raza Mirza,Domenica Lorusso,Amit M. Oza,A. du Bois,Ignace Vergote,Alexander Reuss,Monica Bacon,M. Friedlander,Dolores Gallardo-Rincón,Florence Joly,Suk-Joon Chang,Annamaria Ferrero,Richard J. Edmondson,P. Wimberger,Johanna Mäenpää,David K. Gaffney,Rongyu Zang,Aikou Okamoto,Gavin Stuart,Kazunori Ochiai +22 more
TL;DR: This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC), which was held in Tokyo, Japan, in November 2015.
Journal ArticleDOI
Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland
TL;DR: Using the levonorgestrel-releasing intrauterine system for treatment of menorrhagia during reproductive years was associated with a lower incidence of endometrial, ovarian, pancreatic, and lung cancers than expected and a higher than expected incidence of breast cancer.
Journal ArticleDOI
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Kathleen N. Moore,Kathleen N. Moore,Michael A. Bookman,Jalid Sehouli,Austin Miller,Charles K. Anderson,Giovanni Scambia,Tashanna Myers,Cagatay Taskiran,Katina Robison,Johanna Mäenpää,L. Willmott,Nicoletta Colombo,Jessica Thomes-Pepin,Michalis Liontos,Michael A. Gold,Y. García,Sudarshan K. Sharma,Christopher J. Darus,Carol Aghajanian,Aikou Okamoto,Xiaohua Wu,Rustem Safin,Fan Wu,Luciana Molinero,Vidya Maiya,Victor Khor,Yvonne G. Lin,Sandro Pignata +28 more
TL;DR: In this paper, the authors evaluated the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacsumab in newly diagnosed stage III cancer patients.
Journal ArticleDOI
Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study.
Bengt Sorbe,Britta Nordström,Johanna Mäenpää,Janez Kuhelj,Dimitrij Kuhelj,Sait Okkan,Jean-Francois Delaloye,B. Frankendal +7 more
TL;DR: The conclusions were that the impact of postoperative brachytherapy on even the locoregional recurrence rate seems to be limited in patients with low-risk endometrial carcinoma.